ReviewSynthetic biology (Oxford, England)2021
Biofoundries are a nucleating hub for industrial translation.
Review in Synthetic biology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- High-throughput yeast engineering in biofoundries: towards autonomous and scalable synthetic biology.FEMS yeast research · 2026Review
- Governing Synthetic Biology: A Co-Evolutionary Framework for Sustainable Innovation.Journal of microbiology and biotechnology · 2025Review
- Engineering biology and automation-Replicability as a design principle.Engineering biology · 2024Review
- Public biofoundries as innovation intermediaries: the integration of translation, sustainability, and responsibility.The Journal of technology transfer · 2024Article
- Enabling technology and core theory of synthetic biology.Science China. Life sciences · 2023Review
- Advancing reproducibility can ease the 'hard truths' of synthetic biology.Synthetic biology (Oxford, England) · 2023Review
- A SynBio community comes of age: Political, academical, industrial, and societal developments in the Netherlands.Biotechnology notes (Amsterdam, Netherlands) · 2022Article
- Microbes of traditional fermentation processes as synthetic biology chassis to tackle future food challenges.Frontiers in bioengineering and biotechnology · 2022Article
- Bioeconomy in India: Policy, Prospects and Perspective.Engineering biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Contemporary synthetic biology embraces the entire innovation pipeline; it is a transformative technology platform impacting new applications and improving existing industrial products and processes. However, challenges still emerge at the interface of upstream and downstream processes, integral to the value chain. It is now clear that biofoundries have a key role to play in addressing this; they provide unique and accessible infrastructure to drive the standardization necessary to deliver systematic design and engineering of biological systems and workflows. As for other biofoundries, the success of the London Biofoundry has been in part due to its expertise in establishing channels for industrial translation through its extensive strategic collaborations. It has also become cemented as a key component of various consortia and partnerships that serve the broader bioeconomy and industrial strategies. Adopting a networked approach enables links to be made between infrastructure, researchers, industrialists and policy makers to de-risk the economic challenges of scale-up, as well as contribute to the growing bioeconomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.